New Alzheimer’s drug appears to slow cognitive decline but is ‘not a breakthrough’
December 09, 2022 at 10:50 AM EST
Lecanemab, the drug being tested by Biogen and Eisai, was found to have a modest benefit to patients in a Phase 3 study.
Photography by Christophe Tomatis